The biotech sector continues to see a strong flow of new venture capital deals, with a flurry of new announcements this week. We saw a diverse set of companies—ranging from AI-driven drug discovery startups to firms advancing radiotherapeutic and oligonucleotide technologies—garner significant investments. Here’s a roundup of the key deals that showcase the current innovation landscape in biotechnology.

To stay informed about the latest funding activities and discover more biotech companies making waves, follow the live feed of biotech funding rounds on VentureRadar.

Sanofi Backs Resalis Therapeutics to Tackle Metabolic Disease

Italy’s Resalis Therapeutics received a strategic investment from Sanofi this week, which will accelerate the company’s development of antisense oligonucleotide therapies for metabolic diseases. Resalis is focusing on inhibiting miR-22, a non-coding RNA involved in regulating lipid metabolism, with promising preclinical data showing the reversal of obesity and hepatic steatosis in animal models

Elektrofi Raises $112.25M to Scale Biologic Delivery Platform

Elektrofi Inc., based in the U.S., announced an oversubscribed $112.25 million Series C round aimed at establishing a commercial-scale GMP manufacturing facility and accelerating its clinical programs. Elektrofi’s proprietary Hypercon™ microparticle technology is making waves by enabling at-home subcutaneous administration of biologics, simplifying patient treatment regimens and improving compliance.

Evommune Secures $115M Series C to Advance Pipeline for Chronic Inflammatory Diseases

Evommune, another U.S.-based biotech, closed a $115 million Series C financing round to propel its clinical-stage pipeline addressing immune-mediated inflammatory diseases. The funds will be used to push forward their programs targeting chronic urticaria and atopic dermatitis into Phase 2 studies. By leveraging the skin as a window into immune function, Evommune has been effectively developing therapies for immune-driven conditions, distinguishing itself through its unique screening platform.

Accenture Ventures Invests in 1910 Genetics

AI-driven drug discovery firm 1910 Genetics received backing from Accenture Ventures this week. 1910 Genetics utilizes its multimodal AI platform to discover both small and large molecule therapeutics. This dual-modality capability is a rare differentiator in the AI drug discovery space, suggesting the potential for far-reaching applications across multiple therapeutic areas.

Leal Therapeutics Secures $45M for CNS Precision Medicines

Leal Therapeutics, a U.S.-based company focused on central nervous system disorders, raised $45 million in financing to advance its precision medicine programs. The company’s platform targets major CNS conditions, utilizing antisense oligonucleotides and small molecules to develop highly targeted therapies. The funding will help the company move forward in addressing critical unmet needs in diseases such as Parkinson’s.

Archon Biosciences Completes $20M Seed Round for Generative Protein Design

Archon Biosciences raised $20 million in a seed funding round to further its generative protein design technologies. Their flagship product, Antibody Cages (AbCs), represents an innovative approach to designing self-assembling nanostructures that could significantly enhance therapeutic potency and biodistribution. This seed funding reflects increased interest in computational approaches to biologics, especially in harnessing protein engineering to overcome existing modality limitations.

XellSmart Raises $14M for iPSC-Derived Therapies

China-based XellSmart Healthcare completed a $14 million Series B1 round to expand its work on induced pluripotent stem cell (iPSC)-derived therapies targeting neurological diseases. With an emphasis on developing scalable, cost-effective solutions for degenerative diseases like Parkinson’s, XellSmart is addressing the unmet need for innovative cell-based therapies in CNS disorders.

Blue Earth Therapeutics Raises $76.5M for Next-Gen Radioligand Therapies

Blue Earth Therapeutics announced the completion of a $76.5 million Series A financing to advance its targeted radioligand therapies for cancer. With a focus on prostate cancer, the company is developing radiotherapeutics designed to deliver potent doses directly to tumors, while limiting damage to surrounding tissues. This precision approach is at the forefront of what we’re seeing in targeted cancer therapies today.

SynOx Therapeutics Expands Series B Funding to €84.8M

Irish biotech SynOx Therapeutics secured additional funding to bring its total Series B financing to €84.8 million. SynOx is in the late-stage clinical development of emactuzumab, a CSF-1 receptor inhibitor for treating Tenosynovial Giant Cell Tumor (TGCT). With a promising Phase 3 program, SynOx aims to address debilitating conditions linked to macrophage-driven pathology, reflecting the heightened interest in targeting the tumor microenvironment.

Axonis Therapeutics Secures $115M Series A for Neurological Disorders

Axonis Therapeutics, a U.S.-based company, raised $115 million in Series A funding to support its development of neuromedicines targeting KCC2, which plays a role in enhancing inhibitory neurotransmission. Their approach aims to bring groundbreaking therapies to patients suffering from spinal cord injuries and other neurological disorders, highlighting a growing area of focus in neurological drug development.

Other Notable Deals

• Kivu Bioscience raised $92 million in Series A funding to advance next-generation antibody-drug conjugates (ADCs) for oncology.
• Aignostics secured $34 million in Series B financing to expand its AI-driven precision pathology offerings.
• Vaxinano received €6 million to support its nasal vaccine R&D programs targeting both human and zoonotic diseases.
• Starget Pharma raised $5.1 million for precision peptide radioligand cancer therapies, supported by their proprietary AI platform.
• Paterna BioSciences raised $6 million in seed funding to further develop its in vitro spermatogenesis technology for addressing male infertility.

This week’s financing rounds illustrate a diverse mix of innovation—from novel drug modalities and targeted radiotherapeutics to AI-enabled drug discovery—positioning these biotech players for potential breakthroughs that could reshape healthcare delivery and patient outcomes.

Subscribe for alerts on new companies featured on Startups.Bio

View all recently featured startups